In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ipragliflozin Drug Master File in Korea (Ipragliflozin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ipragliflozin. The MFDS reviews the Ipragliflozin KDMF as part of the drug registration process and uses the information provided in the Ipragliflozin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ipragliflozin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ipragliflozin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ipragliflozin suppliers with KDMF on PharmaCompass.